CSTL Stock Summary and Trading Ideas (Castle Biosciences | NASDAQ:CSTL)

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Castle Biosciences trades on the NASDAQ stock market under the symbol CSTL.

As of April 25, 2024, CSTL stock price declined to $19.51 with 171,246 million shares trading.

CSTL has a beta of 0.70, meaning it tends to be less sensitive to market movements. CSTL has a correlation of 0.01 to the broad based SPY ETF.

CSTL has a market cap of $538.22 million. This is considered a Small Cap stock.

Last quarter Castle Biosciences reported $66 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.44.

In the last 3 years, CSTL stock traded as high as $78.92 and as low as $9.26.

The top ETF exchange traded funds that CSTL belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

CSTL has underperformed the market in the last year with a price return of -13.7% while the SPY ETF gained +25.6%. CSTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.5% and -6.1%, respectively, while the SPY returned +3.5% and -2.8%, respectively.

CSTL support price is $19.28 and resistance is $20.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CSTL stock will trade within this expected range on the day.